Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients ≥18 years of age~* Histologically documented diagnosis of malignant MPNST~* Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months.~Exclusion criteria:~* Patient has received any other investigational agents within 28 days of first day of study drug dosing.~* Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.~* Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control.~* Known CNS metastases~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STI571 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).